Management of anterior chamber dislocation of a dexamethasone intravitreal implant: A case report

被引:0
|
作者
Pacella F. [1 ]
Agostinelli E. [2 ]
Carlesimo S.C. [1 ]
Nebbioso M. [1 ]
Secondi R. [1 ]
Forastiere M. [1 ]
Pacella E. [1 ]
机构
[1] Department of Sense Organs, Faculty of Medicine and Dentistry, Sapienza University of Rome, Viale del Policlinico, Rome
[2] Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome
关键词
Case report; Cystoid macular edema; Intravitreal dexamethasone implant; Ozurdex; Ozurdex dislocation;
D O I
10.1186/s13256-016-1077-2
中图分类号
学科分类号
摘要
Background: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber. Case presentation: An 83-year-old white woman presented to our Emergency Unit complaining of pain and vision loss in herright eye lasting a week. Her anamnesis revealed a history of persistent cystoid macular edema after phacoemulsification with scleral-fixated posterior chamber intraocular lens implantation, recently treated with an intravitreal Ozurdex implant. She also took a long-distance flight 2 days after the injection. An anterior segment examination showed corneal edema and the rod implant adherent to corneal endothelium. To avoid corneal decompensation, we opted for a implant repositioning. Under topical anesthesia, a 30-gauge needle was introduced through a limbar incisionto mobilize the dislocated rod. Balanced saline solution was injected, with a successful repositioning of the implant into the vitreous cavity. Topical 5 % hypertonic saline solution and 0.2 % betamethasone associated with 0.5 % chloramphenicol drops were administered four times a day. To prevent redislocation of the Ozurdex implant, she was instructed to avoid prone position, any kind of physical effort, and not to undertake long-distance flights during the first postoperative week. One week after surgery, an anterior segment examination showed an improvement of corneal edema. Funduscopy showed that the Ozurdex implant was settled into the vitreous cavity. Conclusions: Anterior chamber dislocation of Ozurdex from the vitreous cavity is rare. In our patient, in addition to the posterior capsule tearing, the long-distance flight could have contributed to implant dislocation. Repositioning of the implant is necessary to avoid endothelial decompensation. It can be carried out by using saline balanced solution with the same efficacy as other surgical procedures reported in the literature. A possible disadvantage of this procedure could be implant migration. © 2016 The Author(s).
引用
收藏
相关论文
共 50 条
  • [21] Modified No-Touch Technique for Removal of a Dexamethasone Implant that has Migrated to the Anterior Chamber
    Stewart, Jay M.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 238 - 239
  • [22] Reverse engineering the Ozurdex dexamethasone intravitreal implant
    Costello, Mark A.
    Liu, Joseph
    Wang, Yan
    Qin, Bin
    Xu, Xiaoming
    Li, Qi
    Lynd, Nathaniel A.
    Zhang, Feng
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 634
  • [23] Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis
    Ruti Sella
    Merih Oray
    Ronit Friling
    Lewaa Umar
    Ilknur Tugal-Tutkun
    Michal Kramer
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253 : 1777 - 1782
  • [24] Dexamethasone intravitreal implant (OzurdexA®) for pediatric uveitis
    Sella, Ruti
    Oray, Merih
    Friling, Ronit
    Umar, Lewaa
    Tugal-Tutkun, Ilknur
    Kramer, Michal
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (10) : 1777 - 1782
  • [25] Anterior segment migration of dexamethasone implant: risk factors, complications, and management
    Rahimy, Ehsan
    Khurana, Rahul N.
    CURRENT OPINION IN OPHTHALMOLOGY, 2017, 28 (03) : 246 - 251
  • [26] Intravitreal dexamethasone implant results in the treatment of non-infectious uveitis
    Dikmen, Nejla Tukenmez
    Vural, Ece Turan
    Yenerel, Nursal Melda
    Dikkaya, Funda
    Elibol, Emine Savran
    Kockar, Alev
    NORTHERN CLINICS OF ISTANBUL, 2022, 9 (06) : 638 - 645
  • [27] Disloziertes Dexamethason-Implantat in der Vorderkammer: ein FallberichtAnterior chamber migration of a dexamethasone implant: a case report
    Bujar Berisha
    Lukas Höflechner
    Andreas Wedrich
    Spektrum der Augenheilkunde, 2021, 35 (2) : 83 - 87
  • [28] Intravitreal Dexamethasone Implant in Patients with Persistent Macular Edema of Variable Etiologies
    Sorkin, Nir
    Loewenstein, Anat
    Habot-Wilner, Zohar
    Goldstein, Michaela
    OPHTHALMOLOGICA, 2014, 232 (02) : 83 - 91
  • [29] Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature
    Boscia, Giacomo
    Feo, Alessandro
    Savastano, Alfonso
    Viggiano, Pasquale
    Landini, Luca
    Clemente, Arcangelo
    Scotti, Giacomo
    Grassi, Maria Oliva
    Parisi, Guglielmo
    Giancipoli, Ermete
    Alessio, Giovanni
    Boscia, Francesco
    Mastropasqua, Rodolfo
    Reibaldi, Michele
    Romano, Mario R.
    Borrelli, Enrico
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2025,
  • [30] Cytomegalovirus Retinitis Associated With Intravitreal Dexamethasone Implant Injection
    Shoji, Marissa K.
    Sengillo, Jesse D.
    Shetty, Akaanksh
    Uhr, Joshua
    Sridhar, Jayanth
    JOURNAL OF VITREORETINAL DISEASES, 2024, 8 (02) : 215 - 219